• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

A $26.9-million project to create better psychiatric medications without side effects

Bioengineer by Bioengineer
June 16, 2020
in Chemistry
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: UNC School of Medicine

CHAPEL HILL, NC – June 16, 2020 – Rapidly acting drugs to treat depression, anxiety, or substance abuse without side effects do not exist. Researchers led by Bryan L. Roth, MD, PhD, the Michael Hooker Distinguished Professor of Pharmacology at the UNC School of Medicine, are trying to change that.

With a four-year, $26,975,142 cooperative agreement from the Defense Advanced Research Project Agency (DARPA), Roth and colleagues will use new structural biology and computational approaches to create new medicines that work rapidly and effectively without serious side effects.

“Depression, anxiety, and substance abuse affect large segments of the population. Creating safe, rapidly acting and more effective medications would revolutionize the treatment of these disorders thereby diminishing death and disability,” said Roth, who also directs the National Institute of Mental Health Psychoactive Drug Screening Program, based at UNC-Chapel Hill. “Although drugs like ketamine and potentially psilocybin have rapid antidepressant actions, their hallucinogenic, addictive, and disorienting side effects make their clinical use limited. Our team has developed innovative methods and technologies to overcome these limitations with the goal of creating better medications to treat these neuropsychiatric conditions.”

The research project includes Georgios Skiniotis, PhD, and Ron Dror, PhD, from Stanford University; Jian Jin, PhD, from Icahn School of Medicine at Mt. Sinai; Brian Shoichet, PhD, and Nevan Krogan, PhD, from UC-San Francisco; and William Wetsel, PhD, from Duke University.

Approximately 30 percent of FDA approved medications target molecules on the surface of cells called G protein-coupled receptors (GPCRs) to mediate their therapeutic actions. Drugs like caffeine – the stimulant in coffee and tea – bind to these types of receptors to trigger a cascade of effects inside cells to stop a naturally occurring brain chemical from making us feel tired. Caffeine can have other effects due to that cascade of intercellular actions, but such effects are generally mild. Other drugs that aim to treat more serious problems, such as some used to treat depression, can partially alleviate these symptoms but often not without severe side effects. These side effects, which can include weight gain, sleepiness, and dry mouth, occur because medications do not precisely target the GPCRs. Similar side effects due to this lack of specificity plagues most medications that target GPCRs.

Roth and colleagues have been working to overcome this problem over the past several years by harnessing sophisticated and cutting-edge technologies including lipidic cubic-phase x-ray crystallography, cryo-electron microscopy, and ultra-large-scale computational chemistry to determine how drugs bind to and affect the activity of these receptors. Importantly, the researchers have developed new techniques to fully elucidate how drugs might affect signal processes inside cells to create drugs that are more effective.

“Designing drugs to stabilize these specific cell-signaling complexes represents a ‘grand challenge’ for neuropsychiatric drug discovery, as there are currently no FDA-approved medications with the desired signaling profiles,” said Roth, who also holds a faculty appointment at the UNC Eshelman School of Pharmacy. “We will take advantage of our recent innovations in GPCR structural determination to stabilize specific serotonin receptors and identify tens to hundreds of thousands of new candidates for developing better medications.”

He added, “Rapidly acting drugs with antidepressant, anti-anxiety, and anti-addictive potential devoid of disabling side effects do not exist, not even as experimental compounds for use in animals. Creating such compounds would change the way we treat millions of people around the world suffering from these serious and life-threatening conditions.”

###

This project is sponsored by the Defense Advanced Research Projects Agency (DARPA), which is part of the United States Department of Defense. The views, opinions, and/or findings contained in this material are those of the authors and should not be interpreted as representing the official views, policies, or endorsement of the Department of Defense or the U.S. Government.

Media Contact
Mark Derewicz
[email protected]

Original Source

http://news.unchealthcare.org/news/2020/june/roth-leads-26-9-million-project-to-create-better-psychiatric-medications

Tags: AddictionAlcoholDepression/AngerMedicine/HealthMental HealthPharmaceutical ChemistryPharmaceutical SciencePharmaceutical SciencesPharmaceutical/Combinatorial ChemistryStress/Anxiety
Share12Tweet8Share2ShareShareShare2

Related Posts

Bright Excitons Enable Optical Spin State Control

Bright Excitons Enable Optical Spin State Control

August 3, 2025
blank

Flame Synthesis Creates Custom High-Entropy Metal Nanomaterials

August 2, 2025

Innovative Acid-Base Bifunctional Catalyst Enhances Production of Essential Lithium-Ion Battery Material

August 1, 2025

Oven-Temperature Treatment (~300℃) Enhances Catalyst Performance by Six Times

August 1, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    49 shares
    Share 20 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Predicting Glioma Response to Chemoradiation

Flexible Eddy Current Arrays Detect Cracks in Steel

CagriSema Promotes Rat Weight Loss by Balancing Energy

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.